Alpha-2 Agonist and Inositol Combination for ASD Symptom Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Autistic Spectrum Disorder (ASD) often fail to effectively address the core symptoms and associated symptoms such as impulsivity, concentration deficit, and emotional lability/irritability, leading to misdiagnosis and inappropriate treatment, especially in a subpopulation that comprises about 80% of ASD patients.
Innovation Solution
Administering a therapeutically effective amount of an alpha-2 adrenergic agonist in an extended release dosage form, such as clonidine or guanfacine, in combination with inositol, to reduce the severity of ASD symptoms, including impulsivity, concentration deficit, and emotional lability/irritability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for ASD, then treatment is provided, but the core symptoms and associated symptoms are not effectively addressed
Solution Approach 1:
The patent combines alpha-2 adrenergic agonists (clonidine or guanfacine) with inositol in a single treatment regimen. This combination therapy addresses both core ASD symptoms and associated symptoms (impulsivity, concentration deficit, emotional lability) more effectively than either medication alone, resolving the contradiction between treatment provision and symptom effectiveness.
2Reliability
If alpha-2 adrenergic agonist and inositol are administered in combination, then symptom reduction is achieved, but treatment complexity increases
Solution Approach 1:
The patent merges two medications into a coordinated treatment regimen where alpha-2 adrenergic agonists and inositol work synergistically. This combination is administered in a standardized manner (extended-release formulation of alpha-2 agonist plus inositol) that, while involving two agents, provides a unified treatment approach that reduces overall regimen complexity compared to trial-and-error polypharmacy.
3Reliability
If extended release dosage form is used, then symptom control is improved, but manufacturing complexity increases
Solution Approach 1:
The patent specifies using extended-release dosage forms for alpha-2 adrenergic agonists, which modify the release parameters of the medication to provide sustained therapeutic levels. This parameter change (from immediate-release to extended-release) improves symptom control stability while relying on established pharmaceutical manufacturing techniques for extended-release formulations.
Data Source
AI summary
A method for treating a patient having ASD is disclosed. The method includes administering to the patient a therapeutically effective amount of an alpha-2 adrenergic agonist in an extended release dosage form in combination with a therapeutically effective amount of inositol.